View Older Stories
-
Jefferies finds AI drives up to 50% cost cuts in drug development
-
FDA issues draft guidance to reduce animal testing for cancer drugs
-
IQVIA expands partnership with Kexing Biopharm for biosimilar development
-
IQVIA Holdings (IQV) Tops Q1 EPS by 8c ; Offers Guidance
-
IQVIA Holdings (IQV) PT Lowered to $210 at BMO Capital into earnings
-
Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
-
IQVIA launches AI platform powered by NVIDIA technology
-
TD Cowen Upgrades IQVIA Holdings (IQV) to Buy
-
Barclays Upgrades IQVIA Holdings (IQV) to Overweight
-
RBC Capital Starts IQVIA Holdings (IQV) at Outperform
-
IQVIA Holdings (IQV) PT Lowered at TD Cowen; 'AI Is New Overhang For Valuation'
-
IQVIA Holdings (IQV) PT Lowered to $250 at BMO Capital
-
IQVIA Holdings (IQV) PT Lowered to $255 at Jefferies
-
IQVIA Holdings (IQV) PT Lowered to $225 at Evercore ISI
-
IQVIA Holdings (IQV) Tops Q4 EPS by 2c, provides guidance
-
IQVIA partners with Boehringer Ingelheim for global data platform
-
IQVIA Holdings (IQV) PT Raised to $273 at Stifel
-
Morgan Stanley Assumes IQVIA Holdings (IQV) at Overweight
-
TD Cowen Downgrades IQVIA Holdings (IQV) to Hold
-
Baird Upgrades IQVIA Holdings (IQV) to Outperform
-
IQVIA Holdings (IQV) Tops Q3 EPS by 3c; offers guidance
-
HSBC Upgrades IQVIA Holdings (IQV) to Buy
-
CFRA Upgrades IQVIA Holdings (NYSE: IQV) to Buy
-
Jefferies Upgrades IQVIA Holdings (IQV) to Buy
-
IQVIA Holdings (IQV) PT Raised to $206 at TD Cowen; 'Could We Be Reaching The Bottom?'
-
IQVIA Holdings (IQV) PT Raised to $195 at Jefferies
-
IQVIA Holdings (IQV) PT Raised to $220 at Evercore ISI
-
IQVIA Holdings (IQV) Tops Q2 EPS by 4c; offers guidance
-
Increasing unusual option volume: IQV NTRS EYE XLB NVTS PHG UMC
-
IQVIA Holdings (IQV) Launches New AI Agents for Life Sciences and Healthcare
-
IQVIA Holdings (IQV) Prices $2B Senior Notes Offering
-
IQVIA Holdings (IQV) Announces $2B Senior Notes Offering
-
IQVIA Holdings (IQV) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY25 Guidance
-
HSBC Downgrades IQVIA Holdings (IQV) to Hold
-
Truist: 'IQVIA Holdings (IQV) a Favorite Name Heading into 1Q25'; PT Lowered
-
Barclays Downgrades IQVIA Holdings (IQV) to Equalweight
-
TD Cowen Reiterates Buy Rating on IQVIA Holdings (IQV) Following 4Q24 Results
-
IQVIA Holdings (IQV) PT Raised to $263 at Truist as 'Diversified Business Mix Stands Out'
-
IQVIA Holdings (IQV) PT Raised to $250 at Morgan Stanley
-
IQVIA Holdings (IQV) Tops Q4 EPS by 1c, provides guidance
-
BTIG Downgrades IQVIA Holdings (IQV) to Neutral
-
TD Cowen on IQVIA Holdings (IQV): 'We See IQV Best Positioned Into Qtr'
-
IQVIA Holdings (IQV) and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions
-
IQVIA Holdings (IQV) PT Lowered to $261 at Truist Securities Following Investor Day
-
IQVIA Holdings (IQV) PT Raised to $200 at Jefferies
-
IQVIA Holdings (IQV) PT Lowered to $250 at TD Cowen
-
IQVIA Holdings (IQV) PT Lowered to $212 at Baird
-
IQVIA Holdings (IQV) PT Lowered to $260 at Deutsche Bank
-
IQVIA Holdings (IQV) December 210 calls and January 200 puts active
-
IQVIA Holdings (IQV) PT Lowered to $213 at Baird

